Australia Adds Takhzyro to Its Benefits Scheme on Dec. 1

Australia Adds Takhzyro to Its Benefits Scheme on Dec. 1

312913

Australia Adds Takhzyro to Its Benefits Scheme on Dec. 1

Starting on Dec. 1, people with hereditary angioedema (HAE) in Australia will have access to Takhzyro (lanadelumab), an under-the-skin injection to prevent HAE swelling attacks, through Australia’s Pharmaceutical Benefits Scheme (PBS). “Without this PBS subsidy, Australian patients are paying around $241,000 per year for this treatment,” Greg Hunt, Australia’s minister for health and aged care, said in a press release. “From 1 December, they’ll pay $41.30 per script or $6.60 with a concession card.” Hunt noted…

You must be logged in to read/download the full post.